

Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting

April 24, 2017 8:01 AM ET

MALVERN, Pa., April 24, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) inhibitors at the 76th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. The symposium, titled "You Don't Know JAK," will be held on Thursday, April 27, 2017, from 12:00-1:45 PM PST. Poster presentations include:

- **Clinical investigation of JAK inhibitor tofacitinib in scarring alopecias:** Lindsey Bordone, MD, Columbia University, New York, NY, Abstract #075
- **Treatment of vitiligo with topical Janus Kinase inhibitor ruxolitinib:** Brooke Rothstein, Tufts Medical Center, Boston, MA, Abstract #770
- **Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials:** James Chen, PhD, Columbia University, New York, NY, Abstract #397

Dr. Neal Walker, President and Chief Executive Officer, and Dr. Stuart Shanler, Chief Scientific Officer, will be in attendance. Following the poster presentations, there will be a panel discussion and question and answer session with presenters.

Additional information on the 76th Annual Society of Investigative Dermatology Meeting can be found at: <http://www.sidnet.org/news/339026/View-the-2017-Annual-Meeting-Program.htm>

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.

Contact:

Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
mtung@aclaristx.com

Media Contact
Mariann Caprino
TogoRun
917-242-1087
M.Caprino@togorun.com



Aclaris Therapeutics, Inc.